Incyte (STU:ICY) Accounts Payable & Accrued Expense : €771 Mil (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Incyte Accounts Payable & Accrued Expense?

Incyte's quarterly accounts payable & accrued expense increased from Sep. 2023 (€592 Mil) to Dec. 2023 (€629 Mil) and increased from Dec. 2023 (€629 Mil) to Mar. 2024 (€771 Mil).

Incyte's annual accounts payable & accrued expense increased from Dec. 2021 (€454 Mil) to Dec. 2022 (€670 Mil) but then declined from Dec. 2022 (€670 Mil) to Dec. 2023 (€629 Mil).

Incyte Accounts Payable & Accrued Expense Historical Data

The historical data trend for Incyte's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Accounts Payable & Accrued Expense Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

232.48

292.78

453.88

670.09

629.29

Incyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															488.49	598.62	591.57	629.29	770.81

Incyte Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Incyte (STU:ICY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (STU:ICY) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (STU:ICY) Headlines

No Headlines